Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 537,600 shares, a growth of 20.4% from the October 15th total of 446,600 shares. Based on an average daily trading volume, of 100,200 shares, the short-interest ratio is presently 5.4 days. Approximately 4.9% of the company’s shares are short sold.

Aspira Women’s Health Stock Performance

NASDAQ AWH traded up $0.01 during trading hours on Friday, reaching $0.75. 42,823 shares of the company’s stock were exchanged, compared to its average volume of 75,686. The company has a market capitalization of $12.04 million, a price-to-earnings ratio of -0.53 and a beta of 1.44. The company’s 50-day moving average is $0.86 and its two-hundred day moving average is $1.44. Aspira Women’s Health has a one year low of $0.72 and a one year high of $5.65.

Aspira Women’s Health (NASDAQ:AWH) last released its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same period last year, the business posted ($0.28) EPS. Research analysts predict that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on AWH shares. StockNews.com began coverage on Aspira Women’s Health in a report on Wednesday. They issued a “hold” rating for the company. Alliance Global Partners lowered their price target on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.